Skip to Content

Erik P Sulman, MD, PhD

Present Title & Affiliation

Primary Appointment

Associate Professor with Tenure, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2003 Temple University School of Medicine, Philadelphia, PA, MD, Medicine
2003 Temple University School of Medicine, Philadelphia, PA, PHD, Molecular Biology and Cancer Genetics
1993 The University of Pennsylvania, Philadelphia, PA, BA, Biochemistry

Postgraduate Training

2/2006-6/2008 Research Fellowship, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, Kenneth Aldape, M. D.
7/2004-6/2008 Clinical Residency, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Thomas Buchholz, M.D.
7/2003-6/2004 Clinical Internship, Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA, Glenn Eiger, M.D.


Academic Appointments

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2008-8/2014

Honors and Awards

2008 ASTRO Translational Research in Radiation Oncology and Radiology Symposium Travel Award, ASTRO
2007 ASTRO Translational Research in Radiation Oncology and Radiology Symposium Travel Award, ASTRO
2007 Eleanor Montague Prize, The University of Texas M. D. Anderson Cancer Center
2007 Scholar-in-Training Award, American Association for Cancer Research
2007 Young Oncologist Essay Award, American Radium Society
2004-2008 B. Leonard Holman Research Pathway, American Board of Radiology
2003 Intern of the Year, Albert Einstein Medical Center
2000 Scholar-in-Training Award, American Association for Cancer Research-Genetech

Selected Publications

Peer-Reviewed Original Research Articles

1. Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, DeMonte F, Fuller GN, Aldape KD. Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma. Brain Pathol 25(3):266-75, 5/2015. e-Pub 10/29/2014. PMCID: PMC4297750.
2. Li X, Liu Y, Granberg KJ, Wang Q, Moore LM, Ji P, Gumin J, Sulman EP, Calin GA, Haapasalo H, Nykter M, Shmulevich I, Fuller GN, Lang FF, Zhang W. Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene 34(13):1619-28, 3/26/2015. e-Pub 4/21/2014. PMCID: PMC4205227.
3. Niola F, Zhao X, Singh D, Sullivan R, Castano A, Verrico A, Zoppoli P, Friedmann-Morvinski D, Sulman E, Barrett L, Zhuang Y, Verma I, Benezra R, Aldape K, Iavarone A, Lasorella A. Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest 124(9):4134, 9/2014. e-Pub 8/2014. PMCID: PMC4151206.
4. Verma J, Sulman EP, Jhingran A, Tucker SL, Rauch GM, Eifel PJ, Klopp AH. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 88(2):357-62, 2/1/2014. PMID: 24411609.
5. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699-708, 2/2014. PMID: 24552317.
6. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor initiating cells. Stem Cells 32(1):301-12, 1/2014. e-Pub 8/2013. PMCID: PMC3947402.
7. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16(1):81-91, 1/2014. e-Pub 12/2013. PMCID: PMC3870823.
8. Tsai CJ, Sulman EP, Eifel PJ, Jhingran A, Allen PK, Deavers MT, Klopp AH. Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol Oncol 131(3):645-9, 12/2013. e-Pub 4/2013. PMID: 23643871.
9. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WF, Boddeke HW, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP (equal contribution corresponding/senior author), Aldape K. Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma. Cancer Cell 24(3):331-46, 9/2013. e-Pub 8/2013. PMID: 23993863.
10. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 19(16):4392-403, 8/2013. e-Pub 6/2013. PMID: 23804423.
11. Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RG. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev 27(13):1462-72, 7/2013. e-Pub 6/2013. PMCID: PMC3713427.
12. Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK. Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor-Initiating Cells. Cancer Res 73(10):3062-74, 5/2013. e-Pub 3/2013. PMCID: PMC3655088.
13. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer. J Clin Oncol 31(7):895-902, 3/2013. e-Pub 1/2013. PMCID: PMC3577951.
14. Likhacheva A, Pinnix CC, Parikh NR, Allen PK, McAleer MF, Chiu MS, Sulman EP, Mahajan A, Guha-Thakurta N, Prabhu SS, Cahill DP, Luo D, Shiu AS, Brown PD, Chang EL. Predictors of Survival in Contemporary Practice After Initial Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys 85(3):656-61, 3/2013. e-Pub 8/2012. PMID: 22898384.
15. Nilsson CL, Berven F, Selheim F, Liu H, Moskal JR, Kroes RA, Sulman EP, Conrad CA, Lang FF, Andrén PE, Nilsson A, Carlsohn E, Lilja H, Malm J, Fenyö D, Subramaniyam D, Wang X, Gonzales-Gonzales M, Dasilva N, Diez P, Fuentes M, Végvári A, Sjödin K, Welinder C, Laurell T, Fehniger TE, Lindberg H, Rezeli M, Edula G, Hober S, Marko-Varga G. Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium. J Proteome Res 12(1):135-50, 1/2013. e-Pub 12/2012. PMCID: PMC3539432.
16. Niola F, Zhao X, Singh D, Sullivan R, Castano A, Verrico A, Zoppoli P, Friedmann-Morvinski D, Sulman E, Barrett L, Zhuang Y, Verma I, Benezra R, Aldape K, Iavarone A, Lasorella A. Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest 123(1):405-17, 1/2013. e-Pub 12/2012. PMCID: PMC3537192.
17. Likhacheva A, Pinnix CC, Parikh N, Allen PK, Guha-Thakurta N, McAleer M, Sulman EP, Mahajan A, Shiu A, Luo D, Chiu M, Brown PD, Prabhu SS, Chang EL. Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone. J Neurosurg 117 Suppl:38-44, 12/2012. PMID: 23205787.
18. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling. Stem Cells 30(11):2366-77, 11/2012. PMID: 22961641.
19. Pinnix CC, Fontanilla HP, Hayes-Jordan A, Subbiah V, Bilton SD, Chang EL, Grosshans DR, McAleer MF, Sulman EP, Woo SY, Anderson P, Green HL, Mahajan A. Whole Abdominopelvic Intensity-Modulated Radiation Therapy for Desmoplastic Small Round Cell Tumor after Surgery. Int J Radiat Oncol Biol Phys 83(1):317-26, 5/2012. e-Pub 11/2011. PMID: 22104361.
20. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, Turski A, Azodi Y, Yang Y, Doucette T, Colman H, Sulman EP, Lang FF, Rao G, Copray S, Vaillant BD, Aldape KD. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 25(24):2594-609, 12/2011. PMCID: PMC3248681.
21. de Groot JF, Sulman EP, Aldape KD. Multigene sets for clinical application in glioma. J Natl Compr Canc Netw 9(4):449-57, 4/2011. PMID: 21464148.
22. Bonato V, Baladandayuthapani V, Broom BM, Sulman EP, Aldape KD, Do KA. Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics 27(3):359-67, 2/2011. e-Pub 12/2010. PMCID: PMC3031034.
23. Miller CA, Settle SH, Sulman EP, Aldape KD, Milosavljevic A. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMC Med Genomics 4:34, 2011. e-Pub 4/2011. PMCID: PMC3102606.
24. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Genome Atlas Research Network. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell 17(5):510-22, 5/2010. e-Pub 4/2010. PMCID: PMC2872684.
25. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12(2):116-21, 2/2010. e-Pub 12/2009. PMID: 20150378.
26. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K. A multigene predictor of outcome in glioblastoma. Neuro Oncol 12(1):49-57, 1/2010. e-Pub 10/2009. PMID: 20150367.
27. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463(7279):318-25, 1/2010. e-Pub 12/2009. PMID: 20032975.
28. Broom BM, Sulman EP, Do KA, Edgerton ME, Kenneth D. Aldape. Bagged gene shaving for the robust clustering of high-throughput data. Int J Bioinform Res Appl 6(4):326-43, 2010. PMID: 20940121.
29. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of Elective Nodal Irradiation is Associated with Minimal Elective Nodal Failure in Non-Small Cell Lung Cancer. Radiat Oncol 4:5, 2009. e-Pub 1/2009. PMCID: PMC2651897.
30. Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Kies M, Glisson B, Weber R, Garden AS. Imrt Reirradiation of Head and Neck Cancer-Disease Control and Morbidity Outcomes. Int J Radiat Oncol Biol Phys 73(2):399-409, 6/2008. e-Pub 6/2008. PMID: 18556144.
31. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69(5):1409-16, 12/2007. e-Pub 9/2007. PMID: 17904303.
32. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25(16):2288-94, 6/2007. PMID: 17538175.
33. Sulman EP, White PS, Brodeur GM. Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34. Oncogene 23(4):1014-20, 1/2004. PMID: 14749765.
34. Matise TC, Porter CJ, Buyske S, Cuttichia AJ, Sulman EP, White PS. Systematic evaluation of map quality: human chromosome 22. Am J Hum Genet 70(6):1398-410, 6/2002. PMID: 11992248.
35. White PS, Thompson PM, Seifried BA, Sulman EP, Jensen SJ, Guo C, Maris JM, Hogarty MD, Allen C, Biegel JA, Matise TC, Gregory SG, Reynolds CP, Brodeur GM. Detailed molecular analysis of 1p36 in neuroblastoma. Med Pediatr Oncol 36(1):37-41, 1/2001. PMID: 11464901.
36. Hogarty MD, Liu X, Thompson PM, White PS, Sulman EP, Maris JM, Brodeur GM. BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification. Med Pediatr Oncol 35(6):559-62, 12/2000. PMID: 11107117.
37. Hogarty MD, Liu X, Guo C, Thompson PM, Weiss MJ, White PS, Sulman EP, Brodeur GM, Maris JM. Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Med Pediatr Oncol 35(6):512-5, 12/2000. PMID: 11107105.
38. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 18(9):1888-99, 5/2000. PMID: 10784629.
39. White PS, Sulman EP, Porter CJ, Matise TC. A comprehensive view of human chromosome. Genome Res 9(10):978-88, 10/1999. PMID: 10523526.
40. Hogarty MD, White PS, Sulman EP, Brodeur GM. Mononucleotide repeat instability is infrequent in neuroblastoma. Cancer Genet Cytogenet 106(2):140-3, 10/1998. PMID: 9797779.
41. Sulman EP, Dumanski JP, White PS, Zhao H, Maris JM, Mathiesen T, Bruder C, Cnaan A, Brodeur GM. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 58(15):3226-30, 8/1998. PMID: 9699646.
42. White PS, Jensen SJ, Rajalingam V, Stairs D, Sulman EP, Maris JM, Biegel JA, Wooster R, Brodeur GM. Physical mapping of the CA6, ENO1, and SLC2A5 (GLUT5) genes and reassignment of SLC2A5 to 1p36.2. Cytogenet Cell Genet 81(1):60-4, 1998. PMID: 9691177.
43. Maris JM, Jensen J, Sulman EP, Beltinger CP, Allen C, Biegel JA, Brodeur GM, White PS. Human Krüppel-related 3 (HKR3): a candidate for the 1p36 neuroblastoma tumour suppressor gene? Eur J Cancer 33(12):1991-6, 10/1997. PMID: 9516840.
44. White PS, Maris JM, Sulman EP, Jensen SJ, Kyemba SM, Beltinger CP, Allen C, Kramer DL, Biegel JA, Brodeur GM. Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma. Eur J Cancer 33(12):1957-61, 10/1997. PMID: 9516832.
45. Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ, Allen C, Biegel JA, Brodeur GM. Molecular genetic analysis of familial neuroblastoma. Eur J Cancer 33(12):1923-8, 10/1997. PMID: 9516825.
46. Jensen SJ, Sulman EP, Maris JM, Matise TC, Vojta PJ, Barrett JC, Brodeur GM, White PS. An integrated transcript map of human chromosome 1p35-p36. Genomics 42(1):126-36, 5/1997. PMID: 9177782.
47. Reddy UR, Phatak S, Allen C, Nycum LM, Sulman EP, White PS, Biegel JA. Localization of the human Ror1 gene (NTRKR1) to chromosome 1p31-p32 by fluorescence in situ hybridization and somatic cell hybrid analysis. Genomics 41(2):283-5, 4/1997. PMID: 9143508.
48. Sulman EP, Tang XX, Allen C, Biegel JA, Pleasure DE, Brodeur GM, Ikegaki N. ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40(2):371-4, 3/1997. PMID: 9119409.
49. Kuroda H, White PS, Sulman EP, Manohar CF, Reiter JL, Cohn SL, Brodeur GM. Physical mapping of the DDX1 gene to 340 kb 5' of MYCN. Oncogene 13(7):1561-5, 10/1996. PMID: 8875996.
50. Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ, Allen C, Biegel JA, Yanofsky RA, Feldman GL, Brodeur GM. Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res 56(15):3421-5, 8/1996. PMID: 8758905.
51. Maris JM, Jensen SJ, Sulman EP, Beltinger CP, Gates K, Allen C, Biegel JA, Brodeur GM, White PS. Cloning, chromosomal localization, physical mapping, and genomic characterization of HKR3. Genomics 35(2):289-98, 7/1996. PMID: 8661141.
52. Beltinger CP, White PS, Maris JM, Sulman EP, Jensen SJ, LePaslier D, Stallard BJ, Goeddel DV, de Sauvage FJ, Brodeur GM. Physical mapping and genomic structure of the human TNFR2 gene. Genomics 35(1):94-100, 7/1996. PMID: 8661109.
53. Ikegaki N, Tang XX, Liu XG, Biegel JA, Allen C, Yoshioka A, Sulman EP, Brodeur GM, Pleasure DE. Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein-tyrosine kinase gene of the EPH family. Hum Mol Genet 4(11):2033-45, 11/1995. PMID: 8589679.
54. Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, Look AT, Brodeur GM. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55(20):4664-9, 10/1995. PMID: 7553646.
55. White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, Kaufman BA, Biegel JA, Allen C, Hilliard C. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A 92(12):5520-4, 6/1995. PMID: 7777541.
56. Beltinger CP, White PS, Sulman EP, Maris JM, Brodeur GM. No CDKN2 mutations in neuroblastomas. Cancer Res 55(10):2053-5, 5/1995. PMID: 7743501.

Invited Articles

1. Holliday EB, Sulman EP. Tumor Prognostic Factors and the Challenge of Developing Predictive Factors. Curr Oncol Rep 15(1):33-46, 2/2013. e-Pub 12/2012. PMID: 23224629.
2. Koay E, Sulman EP. Management of Brain Metastasis: Past Lessons, Modern Management, and Future Considerations. Curr Oncol Rep 14(1):70-8, 2/2012. e-Pub 11/2011. PMID: 22071681.
3. Settle SH, Sulman EP. Tumor profiling: development of prognostic and predictive factors to guide brain tumor treatment. Curr Oncol Rep 13(1):26-36, 2/2011. PMID: 21082294.
4. Sulman EP, Aldape K. The use of global profiling in biomarker development for gliomas. Brain Pathol 21(1):88-95, 1/2011. PMID: 21129062.
5. Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol 19(3):142-9, 7/2009. PMID: 19464628.
6. Woodward WA, Sulman EP. Cancer stem cells: markers or biomarkers? Cancer Metastasis Review 27(3):459-70, 9/2008. PMID: 18437295.
7. Sulman E, Aldape K, Colman H. Brain tumor stem cells. Curr Probl Cancer 32(3):124-42, May-Jun, 5/2008. PMID: 18501775.
8. Rivera AL, Pelloski CE, Sulman E, Aldape K. Prognostic and predictive markers in glioma and other neuroepithelial tumors. Curr Probl Cancer 32(3):97-123, May-Jun, 5/2008. PMID: 18501774.

Book Chapters

1. Sulman EP, Guerrero M, Aldape K. In: Transcriptional Profiling: Tumor Biology and treatment stratification, in CNS Cancer, Models, Prognostic Factors and Targets, Van Meir, E, Ed., Humana Press, 2008.

Grant & Contract Support

Title: Pre-clinical analysis of targeted agents using glioma cancer stem-like cells
Funding Source: National Brain Tumor Society
Role: Project Leader
Principal Investigator: Alfred Yung
Duration: 2/3/2014 - 2/2/2019
Title: SPORE in Brain Cancer: Prognostic and Predictive Markers to Personalize Medicine for Malignant Glioma
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Frederick Lang
Duration: 9/1/2013 - 8/31/2018
Title: Targeting BRAF-Mutant Melanoma Brain Metastases/Melanoma
Funding Source: Melanoma Research Alliance
Role: Co-Principal Investigator
Principal Investigator: M. Davies, E. Sulman, H. Tawbi
Duration: 5/1/2013 - 4/30/2016

Last updated: 8/4/2015